shutterstock_1661365084_sundry_photography
Sundry Photography / Shutterstock.com
11 January 2022Pharma

PTAB: Roche patent can’t evade IPR under Fintiv

Roche unit Chugai failed to persuade the  US Patent Trial and Appeal Board (PTAB) that it should not institute inter partes reviews (IPRs) of a patent covering Actemra (Atlizumab), a treatment for arthritis under the NHK/Fintiv rule.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
20 November 2026   A US patent board finds two Halozyme patents unpatentable, while a German appeals court overturns an injunction blocking the subcutaneous version of Keytruda, marking two setbacks for Halozyme in its ongoing dispute with the pharma giant.
Pharma
18 November 2026   A heated dispute over Boehringer’s diabetes drug empagliflozin has ended in a split decision, with the judge drawing a sharp line between what a patent discloses and what can be inferred from it.
Pharma
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.